SOURCE: Medistem Laboratories

April 23, 2008 09:11 ET

Independent Confirmation That Menstrual Derived Stem Cells Have Utility in Fighting Disease

Medistem Applauds Japanese Publication

SAN DIEGO, CA and SCOTTSDALE, AZ--(Marketwire - April 23, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM), a biotechnology company dedicated to commercialization of its novel, universal donor, stem cell population, the Endometrial Regenerative Cell (ERC), applauds a recent publication from an independent Japanese group describing a similar cell type to Medistem's ERC from the same source: menstrual blood.

The recent publication "Hida et al. Novel Cardiac Precursor-Like Cells from Human Menstrual Blood-Derived Mesenchymal Cells. Stem Cells. 2008 Apr 17 [Epub ahead of print]" describes a stem cell population capable of not only becoming heart tissue in vitro, but also having ability to repair injured hearts in animal models of heart attacks.

"These recent data provide independent unbiased verification of the presence of functional stem cells in the menstrual blood," said Thomas Ichim, CEO of Medistem. He continued, "Our previous publication and patent applications describe a cell population with phenotypic and functional similarities to the cells of Hida et al. We are pleased to have aspects of our work successfully reproduced and advanced by scientists at the prestigious Keio University School of Medicine, Tokyo."

In November 2007, an international group of scientists lead by Medistem announced the discovery of the "Endometrial Regenerative Cell," a menstrual blood derived stem cell that could differentiate into 9 major tissues, produce high levels of therapeutic factors, and was capable of massive in-vitro expansion. The study, which is freely available at was awarded BioMed Central's Best Publication in Medicine of 2007.

"Medistem has more than 15 patent families dealing with adult stem cell therapeutics. The recent publication provides additional support for the menstrual blood derived stem cell populations as a viable alternative to embryonic stem cells," said Neil Riordan, Chairman of Medistem.

About Medistem Laboratories

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. Due to Medistem's relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information